Multiple Sclerosis Market Forecast

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
Family Elder
Posts: 599
Joined: Sat Jun 12, 2010 2:00 pm
Location: Montreal

Multiple Sclerosis Market Forecast

Post by erinc14 » Sun Jul 25, 2010 7:26 am

Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...

<shortened url>

i guess ccsvi is a"threat" :x

Post Reply
  • Similar Topics
    Last post